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Abstract 
The purpose of this study was to further understand the mechanisms involved in ultrasound– 
mediated delivery of DNA (sonoporation); in particular, to understand how a plasmid should be 
formulated with an ultrasound contrast agent (UCA).  Different polymer adjuvant-UCA 
combinations were formulated, and their impact on in vitro DNA transfection, was determined, 
under various experimental conditions.  When present in the medium surrounding a cell 
suspension, and in the presence of a plasmid encoding for the green fluorescent protein (GFP), 
expression following sonoporation was increased by more than 1.5-fold compared to that 
achieved in control experiments (without the adjuvants).  The effects of the adjuvants were not 
influenced by the nature of the UCA, nor that of the transfected cells; in contrast, the adjuvant 
concentrations, their physicochemical properties, and the manner in which they were used, did 
have an impact on transfection.  Close association of the adjuvants to the UCA inhibited their 
action, suggesting that these substances must have access to the cell membrane to be effective. 
Indeed, Pluronic® F127 appeared to improve the efficacy of transfection (%GFP-positive cells 
and cell viability), via fluidization of the cell membrane, perhaps facilitating thereby the 
formation of transient pores and their re-sealing.  The mechanism of action of PEG, on the other 
hand, remains unclear. 
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Introduction 
Ultrasound–mediated delivery of DNA (sonoporation) is a relatively new and promising method 
for gene therapy (1-5). Compared to viral and non-viral transfection techniques, sonoporation 
introduces the genetic material into cells or tissues with high spatial and temporal specificity and 
control, and with minimal toxicity. However, the approach is yet to realize its full potential for a 
number of reasons: first, the mechanisms involved in sonoporation are not completely 
understood; second, the technology is complex; and third, the manner in which a plasmid should 
be formulated with an ultrasound contrast agent (UCA), i.e., gas-filled microbubbles or 
microcapsules, has not been investigated in terms of physico-chemical composition, in any detail 
whatsoever. These issues clearly need to be addressed and, to a certain extent, resolved, before a 
safe, effective and practical treatment can be evolved.  This work contributes to the further 
elucidation of the mechanism(s) of sonoporation, and focuses on the impact of the UCA 
formulation (6-8). In the present study, it was hypothesized that some biocompatible polymers 
used as pharmaceutical adjuvants in drug formulation such as polyethylene glycols (PEG) and 
amphiphilic molecules such as Pluronic®, Tween® and Triton X-100 could be useful for 
improving the efficacy of sonoporation since these polymers have been known for their capacity 
to increase the fluidity, permeability of cell membrane (9, 10); to preserve and repair against 
membrane damage (11-13); to facilitate drug and plasmid transport and to enhance gene transfer 
(14-17). Thus, the effect of polymer adjuvants (Pluronic F127, F68 and L61, PEG 4000 and PEG 
35000) to the UCA on DNA transfection has been assessed under a range of experimental 
conditions (different cell types transfected, different adjuvants and UCA, and different 
incubation methods). The additional or synergistic effect of the adjuvant to UCA was evaluated 
with the efficacy of transfection (%cells positive to reporter protein GFP; and cell viability post­
sonoporation). The effect of polymeric adjuvants (PEG4000 and Pluronic® F127) on cell 
membrane fluidity was further assessed by measuring fluorescence anisotropy and compared 
with the results of the transfection. 
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Materials and Methods 
Cell culture 
Rat mammary carcinoma cells (MAT B III, CRL-1666, ATCC-LGC) were incubated at 37°C, in 
225 cm2 tissue culture flasks in a solution of MacCoy’s 5A medium containing Glutamax (Life 
Technologie, Basel, Switzerland), and supplemented with 10% v/v foetal calf serum (FCS) and 
1% v/v antibiotics (initial concentration: 10,000 IU/ml Penicillin, 10,000 μg/ml Streptomycin, 25 
μg/ml Fungizone, Bioconcept, Alschwil, Switzerland) under a 5% CO2 atmosphere. 
Human embryonic kidney cells (HEK 293-H, 11631-017, GIBCO) were incubated at 37°C, 5% 
CO2 atmosphere in 75 cm2 tissue culture flasks in a DMEM medium supplemented with 10% 
FCS and 1% non-essential amino acids, under a 5% CO2 atmosphere. Prior to ultrasound 
exposure, 293-H cells were carefully detached from culture flasks using 0.05% trypsin solution 
containing 0.53mmol of EDTA. All cells were re-suspended in the culture medium without FCS 
for ultrasound exposure. 
Ultrasound exposure 
In a 3 ml polystyrene round-bottom tube, serving as ultrasound exposure chamber, 500 µl of cell 
suspension (1 x 106 cells/ml) were mixed with 5 µg of plasmid gWizTM-GFP (Aldevron, Fargo, 
ND, USA) encoding for the green fluorescent protein (GFP) and an ultrasound contrast agent 
(UCA) consisting of 15 x 106 microcapsules (i.e., a particle-to-cell ratio of 30 capsules/cell). The 
UCAs used were air-filled microcapsules made of tripalmitine (BG1593 and BG1766, Bracco 
Research SA, Geneva, Switzerland). The tube was held in a mechanically rotating system and 
immersed in a water bath thermostated at 37°C. The distance between the tube and the 
ultrasound transducer was 7.6 cm (optimized for a maximum ultrasound exposure). MAT B III 
cells were insonified at a peak negative pressure of 570 KPa for 10 seconds, using a focused 
transducer (Panametrics, Waltham, MA, USA) operating at a transmitted frequency of 2.25 
MHz, a pulse repetition frequency of 100 Hz and a duty cycle of 20%.  Sonoporation was 
performed in the absence or presence of a polymeric adjuvant, either a polyethylene glycol 
(PEG) or a Pluronic®; the surfactants were added to the cell-UCA suspensions at various 
concentrations prior to ultrasound exposure (except in one instance with Pluronic® 127 which 
had been incorporated directly into the UCA shell during its preparation). (Pluronic® F127 and 
F68 were purchased from Sigma Aldrich (Buchs, Switzerland) and Plutonic® L61, PEG 4000 
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and PEG 35000 were purchased from Fluka (Buchs, Switzerland). After sonoporation, the 
suspension was supplemented with 2 ml of cell medium containing 10% of FCS and placed in a 
12-well plate. The cells were incubated at 37°C under a 5% CO2 atmosphere for 24 hours prior 
to the analysis.  
Assay of reporter gene 
GFP-positive cells were analyzed using flow cytometry (FACS Calibur, Becton Dickinson 
Biosciences, Allschwill, Switzerland). After trypsinization, the cell suspension was placed in a 5 
ml polystyrene round-bottom tube and washed twice in phosphate buffered saline (PBS). After 
the last wash, the pellet was re-suspended in 250-300 µl of PBS. Just before analysis, 20 µl of a 
40 µg/ml propidium iodide solution (Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany) was 
added to the sample to assess the cell viability. The results of the flow cytometry analyses were 
expressed as the percentage of cells positive to GFP with respect to the total number of cells 
treated by ultrasound, and in terms of fluorescence intensity, using the software CellQuest Pro 
(Becton Dickinson Biosciences, Allschwill, Switzerland). The percentage of positive cells was 
calculated for the entire sample, including dead cells. The fluorescence intensity was expressed 
in arbitrary units (AU) relative to an internal standard. 
Cell membrane fluidity 
Cell membrane fluidity was measured by fluorescence anisotropy of 1,6-diphenyl-1, 3, 5­
hexanetriene (DPH) (Molecular Probes, Eugene, OR, USA) (18). Briefly, 1 ml of a 2 µM 
solution of DPH was introduced into the cell suspension. The mixture was stirred for one hour in 
the dark at room temperature. Exactly one hour prior to anisotropy measurement, a known 
volume of PEG or Pluronic® F127 solution was added to cell suspension (the final concentration 
of which was 0.5 x 106 cell/ml). Fluorescence intensities were measured using a Fluoromax-1 
spectrophotometer (SPEX Industries, Stanmore, UK), equipped with a polarizer set. The 
fluorescence anisotropy r was calculated from the equation: r = (IVV – GIVH)/(IVV + 2GIVH), 
where IVV is the intensity of the components parallel to the original polarization, IVH is the 
intensity of the components perpendicular to the polarization and G is an instrument factor. The 
excitation wavelength for DPH was 358 nm and the fluorescence intensity was calculated by 
integrating the emission between 420 and 440 nm.  
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Statistical analysis 
All the results (%GFP-positive cells, %viable cells, intensity of GFP-positive cells and 
measurement of fluorescence anisotropy) are reported and displayed as mean ± standard 
deviation. Tests of significance were performed using a one-way analysis of variance (Minitab 
version 13.20, MINITAB Inc., Paris, France), with p<0.05 considered to be statistically 
significant. 
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Results 
Different contrast agents, such as Definity® (Bristol-Myers Squibb Canada, Inc., Saint-Laurent, 
Quebec) and Byk963 (Byk Gulden Lomberg Pharmaceuticals, Clinical Pharmacology, Konstanz, 
Germany), are formulated with adjuvant: the former contains a pegylated phospholipid (DPPE­
PEG 5000), while the latter has Pluronic® F68 introduced during the microbubble preparation 
process (19). BR14 (Bracco Research SA, Geneva, Switzerland), which has already been tested 
in sonoporation experiments, is also prepared in a solution of PEG 4000. As these adjuvants are 
commonly used in pharmaceutical applications, for example to stabilize formulations, their 
potential to enhance ultrasound-mediated gene delivery and/or improve cell viability post­
sonoporation, was considered a useful question to pursue. 
Effect of “free” and “grafted” polymers on transfection 
Air-filled BG 1766 microcapsules were used as control, and the presence of polyethylene glycol 
(PEG) 4000, Pluronic® F68 or Pluronic® F127 was subsequently evaluated. Figure 1 shows that 
all three polymers, when unassociated with the UCA (“free”) in the cell suspension, enhanced 
transfection efficiency as measured by the % of GFP-positive cells (increase from 20% to 30%). 
However, when Pluronic® F127 was incorporated (“grafted”) into the UCA during its 
preparation, transfection (% GFP-positive cells) was not different from the control value.  With 
respect to the fluorescence intensity observed, no differences were found between the 
formulations.  
Concentration and nature of adjuvant 
Sonoporation experiments were performed using different adjuvants at different concentrations. 
Thus, PEGs 4000 and 35000 and Pluronic® F68, F127 and L61 were evaluated for their effect on 
plasmid transfection at two concentrations: 0.05 and 0.1% w/v. The results (Figure 2) showed 
that both PEGs significantly enhanced gene transfection, especially at the lower concentration; 
over 33% of transfected cells were positive to GFP in the presence of PEG 4000 and PEG 35000 
compared to 26.2 ± 0.3% for the control without PEG. Increasing the adjuvant concentration to 
0.1% w/v had no beneficial effect with PEG 35000 (Figure 2A). The Pluronic® behaviour was 
rather complex: Pluronic® L61 decreased transfection, while Pluronic® F68 and Pluronic® F127 
slightly improved gene transfer. In terms of the viability of sonoporated cells, the higher 
concentration (0.1%) of the PEG adjuvants was generally more beneficial; on the other hand, cell 
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viability remained unaffected for the Pluronic®, except for Pluronic® L61 where higher cell death 
was observed (Figure 2B), in agreement with previous results (20), 2006 1 /id}.  
To examine more closely the impact of polymer concentration, a more detailed transfection 
experiment was performed on two cell types, MAT B III and 293-H cells, using Pluronic® L61 at 
levels ranging from 0.0002% to 0.002% w/v. The cells and the Pluronic® concentration range 
were chosen based upon previous results (18;21)} which demonstrated that PL 61 increased 
membrane fluidity at very low concentrations (0.0002-0.002% w/v, or 1-10 μM). For both cell 
types, transfection rates ranged from 15% to 25%.  In the case of MAT B III cells, no differences 
from control were observed at any concentration of Pluronic® (Figure 3A). For 293-H cells, 
0.001 and 0.002% w/v polymer produced a small but significant increase in the % of GFP-
positive cells (p = 0.005 and 0.004 respectively).  Viability was relatively low (40-60%) for both 
cell types over the entire range of polymer concentrations examined (Figure 3B).  Similarly, 
fluorescence intensity was not affected by the concentration of polymer; however, it was noted 
that the fluorescence detected was 3-times higher in 293-H cells than in MAT B III (Figure 3C).  
Timing of adjuvant administration 
To explore whether polymer adjuvants elicit their effects via an action on the plasmid (e.g., DNA 
stabilization) or on the cell membrane (e.g., fluidization), the manner in which PEG 4000 and 
Pluronic® F127 were added to a MAT B III cell suspension before ultrasound exposure, was 
varied: (i) the adjuvant, UCA, and then the DNA were separately added to the cell suspension 
and the mixture was immediately insonified (denoted as “no incubation”); (ii) adjuvant was first 
incubated with the DNA solution for 20 minutes, then mixed with the cell suspension containing 
the UCA and insonified (denoted as “incubation with DNA”); (iii) the adjuvant was first 
incubated with the cell suspension for 20 minutes, then mixed with DNA and UCA, and finally 
insonified (denoted as “incubation with cells”).  
The control experiment utilized the BG1766 UCA together with 10 µg/ml of DNA but without 
adjuvant. Figure 4 shows that the transfection efficiencies with “no incubation” and with 
“incubation with DNA” for both PEG 4000 and PF 127 were similar and significantly better than 
the control (16% ± 1.4 compared to 22% ± 1.2 respectively). Transfection efficiency was 
significantly improved when the adjuvant molecules were first incubated with the cells to be 
transfected, and an increase of about 5% of GFP-positive cells was obtained. However, no 
significant differences were observed between the various preparations with respect to 
fluorescence intensity (data not shown).  
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In all these experiments, adjuvant was introduced before insonification of the cells. 
Subsequently, the Pluronic® was added to the cells after sonoporation; three conditions were 
compared: (a) without adjuvant (control); (b) after 1 hour incubation of PF 127 with the cells 
before sonoporation; and (c) addition of polymer to the cells after ultrasound exposure. Figure 5 
indicates that, when polymer was added immediately after ultrasound exposure, transfection rate 
was decreased 2-fold (p = 0.000) and cell viability, relative to the other conditions, was reduced 
from approximately 70 to 50%. In contrast, when cells were pre-incubated with Pluronic® F127, 
GFP expression rate reached 28% vs 20% for the control conditions. 
Study of membrane fluidity of cells in the presence of adjuvants 
The preceding findings prompt us to evaluate whether the improved transfection in the presence 
of PEG 4000 and PF 127 was directly related to membrane fluidization. Transfection efficiency, 
cell viability and membrane fluidity were therefore evaluated as a function of the polymer 
concentration (0 to 0.1%w/v). Cell membrane fluidity was measured by fluorescence 
polarization of 1,6-diphenyl-1, 3, 5-hexanetriene (DPH)(18).  
Figure 6A shows that transfection efficiency (% GFP-positive cells) in the presence of PF 127 
was well-correlated with measurements of (1/anisotropy). As the fluorescence anisotropy reflects 
the rigidity of the membrane, its reciprocal is logically an expression of membrane fluidity. 
Transfection rate and membrane fluidity increased in parallel with increasing polymer 
concentration before reaching a plateau at 0.05% w/v. The overlap in behaviour between 
transfection and membrane disordering suggests that the mechanism involves bilayer 
fluidization. It should be noted, however, that no correlation was observed between anisotropy 
and fluorescence intensity (data not shown). Also, while the highest polymer concentration 
(0.1% w/v) did not further improve gene transfection nor increase membrane fluidity (Figure 
6A), cell viability increased essentially linearly with adjuvant concentration (Figure 6B).  
Figure 7A demonstrates that PEG 4000 at 0.02% w/v increased significantly transfection rate, 
but that further augmentation of the polymer concentration had no effect. Fluorescence 
anisotropy was not affected; on the other hand, as for Pluronic® F127, and no plateau was 
observed for cell viability at high amounts of PEG 4000. In contrast to Pluronic® F127, cell 
viability progressively increased with PEG 4000 concentration (Figure 7B).  
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Discussion 
PEG has been extensively examined in biochemical and pharmaceutical applications, e.g., for 
membrane fusion (22), as a particle/membrane surface-modulating agent (23) and for membrane 
solubilization (24). Pluronic® (or Poloxamers) are known to enhance the permeation of 
hydrophobic molecules, such as doxorubicin, across cell membranes, to increase membrane 
fluidity (21), and to facilitate gene transfer (25). Equally, the action of both PEGs and Pluronic® 
depend (inter alia) upon their hydrophilic-lipophilic balance and their concentration (21).  
While our work was in progress (26), Chen and co-workers showed that ultrasound alone – i.e. 
without contrast agent - and Pluronic® work synergistically in enhancing gene delivery. 
However, they did not unravel the mechanism of action of the Pluronic molecules. Indeed, we 
showed positive effects of adjuvants, such as PEG 4000 and Pluronic® F68 and F127, on 
transfection efficiency, particularly when the polymers were added “free” to a cell suspension 
(Figure 1); no improvement in transfection was observed when Pluronic® F127 was grafted onto 
the UCA microcapsule shell. This initial result suggested that the adjuvants acted either at the 
cell membrane or at the level of DNA; the polymers’ impact on transfection appeared to be 
independent of contrast agent formulation.  
PEGs and Pluronic® may affect gene transfection at different levels. For example, they may 
interact with plasmid to form a complex which facilitates gene transfer by stabilizing DNA and 
reducing its degradation by cytosolic DNases. Alternatively, the polymers may fluidize cell 
membranes thereby enhancing the extent and duration of ultrasound-induced poration and DNA 
permeation into the cytoplasm; in the same way, membrane re-sealing may be improved 
resulting in higher cell viability. The exact mechanism of action almost certainly depends upon 
many different parameters, such as the polymer hydrophilic-lipophilic balance (HLB) and 
concentration. For the three Pluronic®, their HLB values are quite different: respectively, 3, 22 
and 29 for Pluronic® L61, F127, and F68 (27;28). Likewise, it is known that high PEG 
concentrations (>20% w/v) are necessary to induce membrane fusion, whereas much lower 
levels (0.1-1% w/v) are sufficient to change membrane fluidity (29).  
The transfection of NIH/3T3 cells using PEI-DNA complexes was improved by addition of 
Pluronic® (30). Six different Pluronic® were tested and compared (F68, F127, P105, P94, L122 
and L61). Those with higher HLB, at higher concentration (1 or 3% versus 0.1% w/v), were 
more effective. It was postulated that the polymers protected the DNA complex by sterically 
hindering the access of serum components. Similarly, Pluronic® L61 and F127 significantly 
increased (by an order of magnitude) transfection relative to the naked plasmid in skeletal 
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muscle (25). However, this polymer mixture had no effect on the efficiency of in vitro 
sonoporation in the work presented here (data not shown). The mechanism of gene transfer in 
skeletal muscle remains unclear, although both polymer-DNA complexation and increased cell 
membrane fluidity have been suggested.  
The latter mechanism has been demonstrated for Pluronic® L61 and P85; the degree of effect 
depended upon cell type (normal versus tumor) (18;21). Normal cells appeared to predominantly 
adsorb Pluronic® polymers on their surface, for example. Moreover, Pluronic® L61 increased the 
microviscosity of normal cell (splenocyte) membranes but decreased that of myeloma cells. The 
binding efficiency of the Pluronic® polymers also depended upon their HLB values; for example, 
binding of the hydrophobic L61 (HLB = 3) was 1.5-3 times higher than that of the more 
hydrophilic P85 (HLB = 16). The results in Figure 2B suggest that the relatively hydrophilic 
Pluronic® F68 and F127, may improve cell membrane re-sealing (unlike L61). Cell viability with 
L61 was the lowest among all the adjuvants tested: at concentrations of 0.05% and 0.01% w/v, 
only about 63% and 52%, respectively, of cells were viable. This apparently high toxicity of 
hydrophobic Pluronic® has been reported in vivo. Morphological and biochemical assays 
following injection into muscle tissue indicated that the more hydrophobic the polymer, the more 
severe the lesions induced (31). 
At lower concentrations (0.0002-0.002% w/v), Pluronic® L61 again resulted in cell viabilities of 
~50-60% (Figure 3B), but eventually improved transfection rate to more than 25% (Figure 3A). 
However, the amount of DNA internalized was not affected in the same way (Figure 3C), which 
makes it difficult to draw mechanistic conclusions.  Also intriguing is the observation that 
fluorescence intensities in 293-H cells were 3-fold higher than in MAT B III cells; this would 
imply easier transfection and nuclear uptake in the former despite their longer population 
doubling time (>20 hours compared to 12 hours for MAT B III cells).  
Pluronic® enhanced gene transfer and cell viability even when added shortly before sonoporation 
(Figures 2 and 4). Adsorption of the polymers at the plasma membrane may be very rapid, or the 
polymers might simply be effective at very low surface concentrations. A 20-minute incubation 
of Pluronic® F127 with cells, in the absence of DNA, seemed to further improve transfection 
(Figure 4). This implies that the adjuvant is not acting directly on DNA itself, but that there is a 
polymer effect on the cell membranes. Pre-incubation of the adjuvant with the cells before 
sonoporation would allow more surfactant molecules to adsorb onto and/or integrate into the cell 
membrane. Figure 5 supports this contention in that transfection was enhanced when the 
Pluronic® was present during sonoporation, and was even more successful with pre-incubation.  
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The increase in cell viability with increasing Pluronic® F127 concentration (Figure 6) suggests 
that this adjuvant improves cell repair post-sonoporation. This is consistent with the observation 
that Poloxamer 188 (which is similar to Pluronic® F68: HLB = 29 (28) improved tissue (and cell 
membrane) recovery in a dose-dependent way following electroporation (32). Facilitated re­
sealing of membranes porated by electrical, thermal, or other forces, has been deduced as the 
mechanism of action of this (and other) non-ionic, polymer surfactants (33). It was noted, 
however, that transfection rate reached a plateau at 0.05% w/v PF 127. This may be due to the 
polymer reaching its critical micelle concentration (34;35), at which no further “free” surfactant 
molecules are available for interaction with the cell membrane (34). Alternatively, DNA might 
form a complex with the Pluronic® micelles (36;37), and decrease its availability for transfection. 
The mechanism of action of PEG 4000 in sonoporation is more difficult to understand. PEG can 
fuse lipid bilayers, enhance drug permeation into cells, and repair membranes which have been 
perturbed (21). PEG has also been used to improve gene delivery by lipofection (39). The 
polymer may promote membrane fusion by dehydrating lipid headgroups (40). PEGs can also 
alter membrane fluidity at concentrations ranging from 0.1-1% to 10% w/v (39;41). When gene 
delivery with lipofection (Lipofectamine 2000, Invitrogen, Carlsbag, CA, USA), in the presence 
of 0.05% w/v of PEG 4000, was tested in the present work, no enhancement in transfection rate 
was observed (data not shown). Yet low concentrations of PEG 8000 have induced liposome 
aggregation, and increased the association between cell membranes and lipid/DNA complexes 
(42), leading to better plasmid uptake. Other studies have reported similar results (39;43); for 
example, PEG 8000 at concentrations between 1 and 8% (v/v) increased (by up to 10-fold) the 
transfection of 9L cells by cationic liposomes complexed with plasmid pUT650 (43).  
PEG and Pluronic® polymers are quite different; the former is hydrophilic, the latter amphiphilic. 
The mechanisms of action as adjuvants in DNA delivery may be quite distinct, therefore. The 
fluorescence anisotropy data indicate that Pluronic® PF 127 increases membrane fluidity while 
PEG 4000 does not (Figures 6 and 7). It may be that the concentration of PEG used was simply 
insufficient to provoke any effect; after all, much higher levels are needed to induce membrane 
fusion. Indeed no change in membrane anisotropy was noted across the whole range of PEG 
concentration tested whereas even slight amount of Pluronic 127 decreased anisotropy. This 
demonstrates that PEG and Pluronic may exert their protective action through separate 
mechanisms. It would be of high interest to combine both reagents to unveil potential synergetic 
effects. 
Further speculation on a putative mechanism of action for PEG 4000 in sonoporation is 
inappropriate in the absence of further experiments designed to test specific hypotheses.  Given 
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the quite modest effects observed to-date, the value of a detailed and systematic investigation 
must be weighed against the pursuit of alternative strategies that provide much greater 
enhancement of gene delivery. 
Conclusions 
Polymeric adjuvants present in UCA can improve in vitro transfection and cell viability even at 
moderate concentrations (0.05-0.1% w/v). PEG 4000, and Pluronic® F68, F127, enhanced GFP-
expression more than 1.5-fold compared to the contrast agent alone. The adjuvant effect was 
indifferent to the UCA and cell type used, but strongly depended upon the nature of the polymer, 
the manner in which it was presented to the cells, and its concentration. The adjuvants were not 
effective when grafted to the UCA, suggesting that their adsorption onto, or integration into, the 
cell membrane was necessary for efficacy. Pluronic® F127 appears to fluidize the cell membrane, 
facilitating transient pore formation and re-sealing. The mechanism of action of PEG, on the 
other hand, remains unclear. 
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Abbreviations 
UCA Ultrasound contrast agent 
FCS Foetal Calf Serum 
GFP Green Fluorescent Protein 
DPH 1,6-diphenyl-1, 3, 5-hexanetriene 
HLB Hydrophilic-Lipophilic Balance 
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Legends to Figures 
Figure 1: Effect of adjuvant (PEG 4000, Pluronic® F127, Pluronic® F68 at 0.05%w/v) on 
transfection efficiency (bars) and fluorescence intensity (▲), expressed in arbitrary units (AU), 
using BG1766 microcapsules. Sonoporation was performed at 2.25 MHz (P- = 570 KPa) in the 
presence of 30 capsules/cell (MAT B III). Control is a standard UCA (BG1766) without 
adjuvant. Statistical significance: * =  p < 0.05 versus “free”. 
Figure 2: Effect of the nature and concentration of adjuvant on (A) percentage of GFP-positive 
cells and (B) cell viability. Two adjuvant concentrations were tested: 0.05% w/v (♦) and 0.1% 
w/v (□). Sonoporation was performed at 2.25 MHz (P- = 570 KPa) in the presence of 30 capsules 
BG1593/cell (MAT B III). 
Figure 3: Sonoporation of MAT B III (—▲—) and 293-H (- -□- -) cells in the presence of 
BG1766 (2.25 MHz at P- = 570 KPa, 30 capsules/cell). Effect of Pluronic® L61 concentration on 
(A) percentage of GFP-positive cells, (B) cell viability, and (C) fluorescence intensity expressed 
in arbitrary units (AU). 
Figure 4: Effect of incubation of PEG 4000 (0.05% w/v) and Pluronic® F127 (PF 127 – 0.05% 
w/v) with DNA or with MAT B III cells on transfection efficiency at 2.25 MHz (P- = 570 KPa; 
30 capsules BG1766/cell). Control contained no adjuvant. Statistical significance: * =  p < 0.05 
versus all others; ** = p < 0.05 versus control, no incubation, and incubation with DNA. 
Figure 5: Transfection experiment in the presence of 0.05% w/v Pluronic® F127, under three 
different incubation protocols: in the absence of Pluronic® F127, with the addition of Pluronic® 
F127 1 hour before ultrasound exposure, and with the addition of Pluronic® F127 after 
sonoporation (2.25 MHz, P- = 570 KPa, 30 capsules BG1766/cell). GFP-positive cells (bars) and 
cell viability (♦) were assessed. Control contained no Pluronic® F127. 
Figure 6: Effect of Pluronic® F127 (PF 127) on membrane fluidity, expressed as 1/anisotropy 
(- -□- -) and (A) cell transfection (- -▲- -) or (B) cell viability (- -♦- -). MAT B III cells were 
sonoporated at 2.25 MHz, P- = 570 KPa in the presence of 30 capsules BG1766/cell.  
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Figure 7: Effect of PEG 4000 on membrane fluidity, expressed as 1/anisotropy (- -□- -) and (A) 
cell transfection (- -▲- -) or (B) cell viability (- -♦- -). MAT B III cells were sonoporated at 2.25 
MHz, P- = 570 KPa in the presence of 30 capsules BG1766/cell. 
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